Gilead Sciences acquires our drug for first-in-progress T cell engagement program for autoimmune diseases
FOSTER CITY, Calif.–( BUSINESS WIRE )–Gilead Sciences, Inc. (Nasdaq: GILD) announced today that it has entered into a definitive agreement to acquire Oro Pharmaceuticals, a privately held biotechnology company focused on developing T cell-mediated therapies for autoimmune diseases. “This acquisition underscores our commitment to developing transformative therapies for people living with serious autoimmune diseases,” said … Read more